Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$90,000.00

Characterization of functional synthetic human antibodies specific for the membrane complement regulatory protein CD46

EF 2013-14

Résumé
Human CD46 protein protects cells from the deleterious effects of components of our immune system known as complement system whose function is to help or complement the workings of antibodies. CD46 is also a receptor for a striking array of pathogens such as measles virus, adenovirus, and different strains of bacteria, which together contribute significantly to morbidity and mortality worldwide. For some of these pathogens, CD46 not only mediates entry into the cell but also influences how the host's immune system responds to infection. For example, interactions with pathogens leads to decrease in CD46 levels on the cell surface, which then increases sensitivity of infected cells to complement-mediated killing. As such, tumor cells have learnt to exploit CD46 function by overexpressing it in order to protect themselves from being killed by complement system. On this note, the potential role of complement in the control of cancer cells has been emphasized, as complement is required for the therapeutic activity of anticancer antibodies. I have developed unique synthetic human antibodies whose function is to recognize and bind CD46, and thereby sensitize tumor cells to complement-mediated destruction. These binding reagents were made against CD46 by first designing cell growth conditions for identifying cell surface proteins with features that serve as markers for metabolically reprogrammed cancer cells and applying a novel and unique methodology called Cellectseq. As altered metabolic conditions can lead to changes in cell surface features that influence cell growth, size and motility, my objective is to discern if antibodies that I developed can discriminate between the altered cellular states in order to establish the full potential of anti-CD46 antibodies. Understanding of how antibodies against CD46 function could lead to significant improvements in the effectiveness of antibody-based therapies as well as protect host cells against several viruses and bacteria.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
300898
Name
Tomic Jelena
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of functional synthetic human antibodies specific for the membrane complement regulatory protein CD46
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adjuvant Cancer Therapy; Antibodies; Antibody-Based Immunotherapy; Cancer; Cd46; Complement Regulatory Proteins; Complement System; Immunity; Infectious Agents; Phage Display
Abstract
Human CD46 protein protects cells from the deleterious effects of components of our immune system known as complement system whose function is to help or complement the workings of antibodies. CD46 is also a receptor for a striking array of pathogens such as measles virus, adenovirus, and different strains of bacteria, which together contribute significantly to morbidity and mortality worldwide. For some of these pathogens, CD46 not only mediates entry into the cell but also influences how the host's immune system responds to infection. For example, interactions with pathogens leads to decrease in CD46 levels on the cell surface, which then increases sensitivity of infected cells to complement-mediated killing. As such, tumor cells have learnt to exploit CD46 function by overexpressing it in order to protect themselves from being killed by complement system. On this note, the potential role of complement in the control of cancer cells has been emphasized, as complement is required for the therapeutic activity of anticancer antibodies. I have developed unique synthetic human antibodies whose function is to recognize and bind CD46, and thereby sensitize tumor cells to complement-mediated destruction. These binding reagents were made against CD46 by first designing cell growth conditions for identifying cell surface proteins with features that serve as markers for metabolically reprogrammed cancer cells and applying a novel and unique methodology called Cellectseq. As altered metabolic conditions can lead to changes in cell surface features that influence cell growth, size and motility, my objective is to discern if antibodies that I developed can discriminate between the altered cellular states in order to establish the full potential of anti-CD46 antibodies. Understanding of how antibodies against CD46 function could lead to significant improvements in the effectiveness of antibody-based therapies as well as protect host cells against several viruses and bacteria.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tomic, Jelena
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~